Draft National Health Policy of India and Determining Cost-effectiveness Threshold.
作者信息
Sakharkar Prashant
机构信息
Department of Clinical and Administrative Sciences, Roosevelt University College of Pharmacy, Schaumburg, IL, USA.
出版信息
J Basic Clin Pharm. 2016 Dec;8(1):1-3. doi: 10.4103/0976-0105.195078.
Abstract
摘要
相似文献
1
Draft National Health Policy of India and Determining Cost-effectiveness Threshold.
J Basic Clin Pharm. 2016 Dec;8(1):1-3. doi: 10.4103/0976-0105.195078.
2
National health policy.
J Indian Med Assoc. 1979 Mar 16;72(6):149-51.
3
Draft national health policy of the Government of India.
J Indian Med Assoc. 1979 Mar 16;72(6):132-6.
4
Conceptualizing health policy.
Natl Med J India. 2002 Jul-Aug;15(4):226-31.
6
Draft national health policy 2015: A critical appraisal.
Indian J Public Health. 2016 Jan-Mar;60(1):40-50. doi: 10.4103/0019-557X.177304.
7
India's draft policy criticized.
Popul Headl. 1994 Aug(233):2.
8
The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.
Health Res Policy Syst. 2016 Dec 3;14(1):86. doi: 10.1186/s12961-016-0156-6.
9
Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
Vaccine. 2019 Jan 21;37(4):623-630. doi: 10.1016/j.vaccine.2018.12.004. Epub 2018 Dec 23.
10
Cost-effectiveness of screening for hypo- and hyperthyroidism in India.
Med Decis Making. 1981;1(1):44-58. doi: 10.1177/0272989X8100100107.
引用本文的文献
1
Framework for developing cost-effectiveness analysis threshold: the case of Egypt.
J Egypt Public Health Assoc. 2024 Jun 3;99(1):12. doi: 10.1186/s42506-024-00159-7.
2
Cost-effectiveness of adrenocorticotropic hormone injection and oral prednisolone in patients with West syndrome: A comparative analysis.
J Neurosci Rural Pract. 2023 Jan-Mar;14(1):103-110. doi: 10.25259/JNRP-2022-6-31. Epub 2022 Dec 15.
3
Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All--Retinoic Acid, Arsenic Trioxide, and Daunorubicin for High-Risk Acute Promyelocytic Leukemia.
JCO Glob Oncol. 2020 Nov;6:1749-1756. doi: 10.1200/GO.20.00226.
4
Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy.
Saudi Pharm J. 2020 Oct;28(10):1228-1237. doi: 10.1016/j.jsps.2020.08.013. Epub 2020 Aug 21.
5
Strengthening health technology assessment systems in the global south: a comparative analysis of the HTA journeys of China, India and South Africa.
Glob Health Action. 2018;11(1):1527556. doi: 10.1080/16549716.2018.1527556.
本文引用的文献
1
Financing health care for all: challenges and opportunities.
Lancet. 2011 Feb 19;377(9766):668-79. doi: 10.1016/S0140-6736(10)61884-3. Epub 2011 Jan 10.
2
NICE's cost effectiveness threshold.
BMJ. 2007 Aug 25;335(7616):358-9. doi: 10.1136/bmj.39308.560069.BE.
3
Application of economic analysis to diabetes and diabetes care.
Ann Intern Med. 2004 Jun 1;140(11):972-7. doi: 10.7326/0003-4819-140-11-200406010-00039.
4
Willingness to pay for a quality-adjusted life year: in search of a standard.
Med Decis Making. 2000 Jul-Sep;20(3):332-42. doi: 10.1177/0272989X0002000310.
Zotero 插件